Emerging Role of Pharmacogenetic in Organ Transplantation

The currently used immunosuppressive drugs have a narrow therapeutic index which required to individualize the dose regimen for different recipients. Pharmacogenetic is the use of genetic screening to prevent metabolic responses to different immunosuppressive drugs. Since the oxidative enzymes cytochrome P450 CYP3A and the drug efflux pump P-glycoprotein (P-gp) play a pivotal role in immunosuppressive drugs metabolism, pharmacogenetic studies have been mainly focused on these two enzymes. This would provide an important aid toward drug regimen individualization during the post-transplant therapy and has potential to improve graft outcome. *Corresponding author: Mariano Ferraresso, M.D. Ph.D., Department of Surgical Science, University of Milan, Via San Vittore 12, 20122 Mila, Italy, Tel: +39 0250320382; Fax: +39 0250320384; E-mail: [email protected] Received February 03, 2012; Accepted February 06, 2012; Published February 10, 2012 Citation: Ferraresso M (2012) Emerging Role of Pharmacogenetic in Organ Transplantation. J Transplant Technol Res 2:e110. doi:10.4172/21610991.1000e110 Copyright: © 2012 Ferraresso M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.